News Quarterly

driving faster, better research to improve type 1 outcomes

From a Vision to Reality: You're helping us drive faster, more informed research!

In the world of type 1 diabetes organizations, T1D Exchange is a relatively new face. We began 5 years ago as a vision to accelerate research to improve type 1 outcomes and we've been working towards that vision ever since.

In recent months, it became clear to me that our vision is quickly becoming reality.

T1D Exchange is transforming the way type 1 diabetes research is conducted. How?

  • We start with community needs and wants first and use that to drive research--instead of the other way around.
  • We provide researchers with seamless access to data and resources--that means they get answers faster than ever before.
  • We focus on research we believe is going to tangibly improve outcomes. This type of research might not always make a big splash in the news, but it can truly ease the daily burden of living with type 1.

Want to know more? Watch a mini-documentary film about T1D Exchange and learn how, together with you, T1D Exchange is truly transforming T1D research.

Have a great day!

Dana A. Ball
Executive Director & Founder

T1D Exchange analyzes US T1D treatment

Using data from the Clinic Registry, T1D Exchange conducted a sweeping analysis assessing the current state of diabetes treatment in the U.S. Our researchers conclude that there remains considerable room for improving treatment outcomes in T1D across all age groups, but especially for adolescents and young adults.

Learn More

T1D Exchange Biobank samples at work!

The T1D Exchange Biobank consists of thousands of biological samples and clinical, demographic, and study-derived information from individuals with T1D.

Learn how T1D Exchange Biobank resources are being put to use right now to help researchers better understand type 1 diabetes to improve care and outcomes.

Learn More

T1D Exchange reveals important insights into severe hypoglycemia

Severe hypoglycemia can be a serious health risk as well as scary and upsetting -- not just for the person with T1D but for family and friends as well. T1D Exchange set out to study which factors might be associated with severe hypoglycemia (SH).

Two hundred participants took part in the study. Half of the participants had experienced an SH event in the past year (this group is referred to as "Cases") and the other half had not experienced an SH event in the past 3 years (this group is referred to as "Controls"). Both groups had similar HbA1c levels and mean glucose. They were also similar in terms of other factors such as depression, daily functioning, and diabetes numeracy (this is loosely defined as how skilled someone is at applying math skills to diabetes care).

People with recent SH:

  • had more glucose variability,
  • had greater fear of hypoglycemia,
  • and checked their blood sugar more often.

What was the greatest difference in those who experience SH?

Hypoglycemia unawareness--20% of those with recent SH do not experience symptoms until blood glucose is <40 mg/dl, compared with only 3% of controls who have to get that low before experiencing symptoms.

Evidence based research such as this study will lead to better interventions for those experiencing SH events, such as continuous glucose monitoring (CGM) devices, and may pave the way for affordable access to these devices as well.

View more research results from T1D Exchange

Q3 2015

Accelerate Research: 2 Easy ways to get involved

Participate in Glu

As part of our online community of over 14,000 people touched by T1D, you can answer Question of the Day, participate in real-time research, share experiences and learn from others. Go >>

Join the Living Biobank

Help science advance research and improve lives by providing valuable blood samples from people with T1D. Go >>

What's everyone Glu-ed to?

Meet T1D Exchange Chief Medical Officer, Dr. Henry Anhalt. Go >>

Challenges of Planning a T1D Pregnancy. Go >>

Giving the Bionic Pancreas a Workout:a personal perspective from the Chapel Hill clinical trial. Go >>